Investor Relations
Stock Information
| Ticker | SNTS |
| Exchange | NASDAQ |
| Price | $4.75 |
| Change | + 0.12 |
| Volume | 411,000 |
| Jan 27, 2012 3:59 PM ET | |
Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. The company's current commercial efforts are focused on GLUMETZA® (metformin hydrochloride extended release tablets) and CYCLOSET® (bromocriptine mesylate) tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Santarus also has a diverse development pipeline with three late-stage product candidates in Phase III clinical programs: budesonide MMX® for induction of remission of active ulcerative colitis, RHUCIN® (recombinant human C1 inhibitor) for treatment of acute attacks of hereditary angioedema and rifamycin SV MMX® for treatment of travelers' diarrhea, in addition to other earlier-stage development programs.
Recent Releases
Dec 21, 2011
Santarus Adds FENOGLIDE to Marketed Products Portfolio
Dec 20, 2011
Santarus Submits New Drug Application to FDA for UCERIS (budesonide) Tablets
Events & Presentations
There are no upcoming events at this time.
